A fully human anti-Ep-CAM scFv-beta-glucuronidase fusion protein for selective chemotherapy with a glucuronide prodrug by de Graaf, M et al.
A fully human anti-Ep-CAM scFv-beta-glucuronidase fusion
protein for selective chemotherapy with a glucuronide prodrug
M de Graaf*
,1, E Boven
1, D Oosterhoff
1, IH van der Meulen-Muileman
1, GA Huls
2, WR Gerritsen
1,
HJ Haisma
3 and HM Pinedo
1
1Department of Medical Oncology, Division of Gene Therapy, Vrije Universiteit Medical Centre, PO Box 7057, 1007 MB Amsterdam, The Netherlands;
2Department of Immunology, Utrecht Medical Centre, Utrecht, The Netherlands;
3Department of Therapeutic Gene Modulation, University Centre for
Pharmacy, University of Groningen, PO Box 196, 9700 AD Groningen, The Netherlands
Monoclonal antibodies against tumour-associated antigens could be useful to deliver enzymes selectively to the site of a
tumour for activation of a non-toxic prodrug. A completely human fusion protein may be advantageous for repeated
administration, as host immune responses may be avoided. We have constructed a fusion protein consisting of a human single
chain Fv antibody, C28, against the epithelial cell adhesion molecule and the human enzyme b-glucuronidase. The sequences
encoding C28 and human enzyme b-glucuronidase were joined by a sequence encoding a ﬂexible linker, and were preceded
by the IgGk signal sequence for secretion of the fusion protein. A CHO cell line was engineered to secrete C28-b-
glucuronidase fusion protein. Antibody speciﬁcity and enzyme activity were retained in the secreted fusion protein that had an
apparent molecular mass of 100 kDa under denaturing conditions. The fusion protein was able to convert a non-toxic
prodrug of doxorubicin, N-[4-doxorubicin-N-carbonyl(oxymethyl)phenyl]-O-b-glucuronyl carbamate to doxorubicin, resulting
in cytotoxicity. A bystander effect was demonstrated, as doxorubicin was detected in all cells after N-[4-doxorubicin-N-
carbonyl(oxymethyl)phenyl]-O-b-glucuronyl carbamate administration when only 10% of the cells expressed the fusion protein.
This is the ﬁrst fully human and functional fusion protein consisting of an scFv against epithelial cell adhesion molecule and
human enzyme b-glucuronidase for future use in tumour-speciﬁc activation of a non-toxic glucuronide prodrug.
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Treatment of solid tumours with conventional cytotoxic drugs
lacks selectivity and thus results in toxic dose-limiting side effects.
In addition, the survival of drug-resistant tumour cells will occur
due to insufﬁcient drug concentrations at the site of the tumour.
Selectivity in cancer therapy could be conveyed by monoclonal
antibodies against tumour-associated antigens. These antibodies
have been used as carriers of cytotoxic agents, such as conventional
cytotoxic drugs, radionuclides, or toxins derived from plants or
bacteria. Monoclonal antibodies can also be used for tumour-selec-
tive delivery of an enzyme that converts a relatively non-toxic
prodrug into its toxic drug. This approach is called antibody-direc-
ted enzyme prodrug therapy (ADEPT) (Bagshawe, 1987; Senter et
al, 1988). The idea of using antibodies to localize enzymes to the
tumour was originally conceived by Philpott et al (1973). The
selective activation of the prodrug at the site of the tumour should
enhance the drug concentration in the tumour and result in a
better anti-tumour effect and a reduction of systemic toxicity.
The occurrence of an immune response hampers repeated
administration of a non-human enzyme immunoconjugate, as
prolonged treatment may prove necessary for optimal efﬁcacy
in solid tumours. In the clinical trial reported by Sharma et al
(1992) all patients developed detectable antibodies against the
murine antibody fragment and against the bacterial enzyme with-
in 10 days after a single dose of antibody-enzyme conjugate.
Therefore, it is desirable to use human proteins, as is also under-
lined by the recent clinical progress with engineered human
antibodies (McLaughlin et al, 1998; Pegram et al, 1998; Vincenti
et al, 1998).
A suitable candidate for a human prodrug-converting enzyme
could be human b-glucuronidase (GUSh). GUSh is localised intra-
cellularly in microsomes and lysosomes and its activity is not
detectable in human blood. This enzyme is able to convert a
hydrophilic prodrug of doxorubicin, N-[4-doxorubicin-N-carbonyl
(oxymethyl)phenyl]-O-b-glucuronyl carbamate (DOX-GA3), which
is not able to cross cell membranes (Houba et al, 1996). Therefore,
DOX-GA3 is not available for conversion by the endogenous
enzyme under normal circumstances. An additional advantage of
this human enzyme is the fact that, in larger tumours, the glucur-
onyl-doxorubicin prodrug has an inhibiting effect on tumour
growth on its own (Bosslet et al, 1995; Houba et al, 2001a). The
success of the glucuronyl-doxorubicin prodrug is ascribed to
release of the enzyme from necrotic tumour cells and macrophages
in larger tumours (Bosslet et al, 1998). A potential limitation of
glucuronide prodrugs in monotherapy is that they are not activated
homogeneously throughout the tumour tissue, but only at the site
of necrosis and inﬂammatory cell inﬁltration. Furthermore, small
tumour lesions do not yet contain necrotic areas. The efﬁcacy of
prodrug monotherapy could be increased by exogenous adminis-
tration of targeted b-glucuronidase.
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www.bjcancer.comPrevious studies with monoclonal antibodies against the pan-
carcinoma antigen, epithelial cell adhesion molecule (Ep-CAM),
have shown tumour selectivity (De Bree et al, 1994; Riethmuller
et al, 1994). We have already demonstrated that chemical conju-
gates consisting of the anti-Ep-CAM monoclonal antibody 323/
A3 and GUSh speciﬁcally localised into the Ep-CAM expressing
tumour in nude mice bearing human ovarian cancer xenografts
(Houba et al, 2001b). Administration of the conjugate and DOX-
GA3 in this model resulted in an enhanced inhibition of tumour
growth as compared to that obtained with DOX-GA3 alone. The
production of chemical conjugates, however, is very laborious.
The production of genetic fusion proteins is obviously an attractive
alternative. We have previously shown that fully functional scFv-
GUSh fusion proteins can be produced in mammalian cells
(Haisma et al, 1998a,b). Thus far, the scFvs used were from murine
origin. Genetic fusion of GUSh to a human scFv would result in a
fully human, and as a result in a non-immunogenic, fusion
protein.
In the present study, we constructed a fusion protein consisting
of the genes encoding the human scFv against Ep-CAM (C28) and
GUSh. The fusion protein was expressed in eukaryotic cells,
because GUSh requires N-linked glycosylation for activity (Tabas
and Kornfeld, 1980). The construct contained a signal sequence
at the 5' end for secretion and a myc- and 6His-tag at the 3'
end for easy detection and puriﬁcation. The enzymatic activity,
antibody-binding speciﬁcity, and prodrug activation of the secreted
fusion protein were analysed. We demonstrate that mammalian
cells transduced with the C28-GUSh construct secrete fully func-
tional fusion protein. Therefore, this fully human construct is a
candidate for tumour-speciﬁc activation of the prodrug DOX-GA3.
MATERIALS AND METHODS
Materials
Pwo DNA polymerase, PCR buffer and dNTPs were obtained from
Roche Biochemicals (Almere, The Netherlands). Restriction
enzymes were purchased from New England Biolabs (Beverly,
MA, USA) and Life Technologies (Breda, The Netherlands). The
kits used for DNA isolation, puriﬁcation, and extraction from
agarose gel, were from Qiagen (Hilden, Germany). The
substrate 4-methylumbelliferyl-b-D-glucuronide trihydrate (4-
MuGlu) substrate was purchased from Sigma-Aldrich (Zwijn-
drecht, The Netherlands).
Doxorubicin was derived from Pharmacia and Upjohn (Woer-
den, The Netherlands). The prodrug DOX-GA3 was synthesised
as described (Leenders et al, 1999).
Cell lines
The COS-7 and CHO cell lines were obtained from the American
Type Culture Collection (Rockville, MD, USA) and were grown in
Dulbecco’s modiﬁed Eagle’s medium (DMEM) supplemented with
5% heat-inactivated FCS (Life Technologies) and antibiotics in a
humidiﬁed atmosphere containing 5% CO2 at 378C. The human
ovarian cancer cell line OVCAR-3 (Hamilton et al, 1983) was
grown in DMEM supplemented with 10% FCS and antibiotics.
The human glioma-derived cell line U118 MG (glioblastoma multi-
forme) was obtained from Dr JT Douglas (Gene Therapy Centre,
University of Alabama at Birmingham, Birmingham, AL, USA)
and grown under the same conditions.
Construction of pC28-GUSh
The anti-Ep-CAM scFv C28 was derived from scFv UBS-54, which
was isolated from a semi-synthetic phage antibody display library
in a pHEN vector (Huls et al, 1999). An SﬁI/NotI fragment encod-
ing the scFv C28 was isolated from the pHEN vector and cloned
into the eukaryotic expression vector, pSTCF (Arafat et al, 2000),
containing a secretion signal and a myc- and 6His-tag. The pSTCF
vector was digested with the same enzymes. A ﬂexible (Gly4Ser)2
linker was introduced downstream of C28. For this purpose, two
overlapping primers with 5' phosphorylation were designed (Table
1). Hybridization of the primers resulted in a 5' end that was
compatible with NotI and a 3' end compatible with ApaI. The
primers were designed in such a way that the NotI site at the 5'
end of the linker disappeared upon ligation into the vector. A
new NotI site was introduced at the 3' end of the sequence encod-
ing the linker to allow insertion of GUSh downstream of the
(Gly4Ser)2 linker.
The cDNA encoding GUSh was cloned into the new NotI site at
the 3' end of the linker. Therefore, the NotI site present within the
cDNA encoding GUSh was eliminated ﬁrst. To this end, the cDNA
encoding GUSh (Oshima et al, 1987) was recloned into pcDNA3
(Invitrogen, Groningen, The Netherlands). A primer, GUSh NotI
mut, was designed with one silent mismatch within the sequence
encoding the NotI site and overlying the KpnI site just 5' of the
NotI site (Table 1). A PCR was performed using this primer and
a primer that anneals at the BGH polyadenylation site of
pcDNA3/GUSh. The PCR product was digested with KpnI and
SacII. This fragment containing the mutated NotI site was used
to replace the KpnI/SacII fragment in pcDNA3/GUSh.
The oligonucleotide pair GUSh NotI5 ' and GUSh NotI3 ' was
then used to amplify the cDNA encoding mature GUSh (Table
1). Both primers contained a NotI site at the 5' end. The PCR frag-
ment was cut with NotI, and inserted into the NotI site of the
vector containing C28 with (Gly4Ser)2 linker to obtain pC28-
GUSh.
Expression and puriﬁcation of C28-GUSh fusion protein
To obtain stable transfectants, the pC28-GUSh was transfected into
CHO cells by Lipofectamine Plus reagent (Life Technologies). Cells
were grown in complete culture medium for 48 h. Transfected cells
were selected by limiting dilution in medium containing
800 mgm l
71 zeocin (Invitrogen). Resistant clones were grown in
medium supplemented with 400 mgm l
71 zeocin and screened
for b-glucuronidase activity in culture medium as described below.
b-Glucuronidase activity
Supernatants of stably transfected CHO clones were analysed for b-
glucuronidase activity. To this end, 10 ml supernatant was
suspended in 100 ml1 m M 4-MuGlu in sodium acetate buffer
(pH 4.2) with 0.1% BSA and incubated for 1 h at 378C. The reac-
tion was terminated by the addition of 1 ml 0.1 M glycine/NaOH
pH 10.6 to 50 ml reaction mix. The ﬂuorescent product, 4-methy-
lumbelliferone, was measured using an excitation wavelength of
370 nm and an emission wavelength of 450 nm on the Fluores-
cence Spectrometer 3000 (Perkin Elmer). The stable CHO clone
with the highest amounts of b-glucuronidase activity in the super-
natant, CHO/C28-GUSh, was selected for further experiments.
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Table 1 Primers for introduction of a (Gly4Ser)2 linker and cloning of
GUSh into the expression construct
Sequence (5'?3')
a
Linker forward ggccggaggtggaggctccggaggtggaggctctgcggccgccgggcc
Linker reversed cggcggccgcagagcctccacctccggagcctccacctcc
BGH tagaaggcacagtcgagg
GUSh NotI mut agtggtaccggcgaccgctgtgg
GUSh NotI5 ' gtgtgcggccgcgctgcagggcgggatgctgtacc
GUSh NotI3 ' ttaagcggccgcagtaaacgggctgttttcc
aSequences encoding restriction sites within the primers are presented in italic.
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Western blot analysis was used to assess the size of the fusion
protein. Supernatant from CHO/C28-GUSh (15 ml) was dissolved
in sample buffer (Laemmli, 1970) with 2-mercaptoethanol and
boiled at 958C for 5 min. Samples were subjected to electrophoresis
through a 10% sodium dodecyl sulphate-polyacrylamide gel under
denaturing conditions. Protein bands were subsequently electro-
blotted onto PVDF protein membrane (Bio-Rad, Veenendaal,
The Netherlands). Recombinant C28-GUSh fusion protein was
detected using anti-myc antibody 9E10 (Chan et al, 1987), and
horseradish peroxidase (HRP)-conjugated rabbit anti-mouse IgG
(Dako, Glostrup, Denmark). Blots were developed with Lumilight
Plus (Roche).
FACS analysis
Binding of C28-GUSh to OVCAR-3 cells was determined by FACS
analysis. OVCAR-3 cells were trypsinized for 5 min at 378C,
washed with DMEM, counted and resuspended in PBS. A total
of 0.5610
6 cells were incubated with 50 ml supernatant of CHO/
C28-GUSh or normal CHO cells on ice for 1 h and washed three
times with PBS. Then, cells were incubated with the mouse anti-
myc antibody 9E10 (Chan et al, 1987) in PBS/0.1% BSA, washed
three times with PBS, and stained with ﬂuorescein-conjugated
rabbit anti-mouse IgG (Dako). Stained cells were ﬁxed with 1%
formaldehyde in PBS and analysed on a FACScan ﬂow cytometer
(Becton Dickinson, Erembodegem-Aalst, Belgium).
Cell-associated b-glucuronidase activity
The C28-GUSh fusion protein in supernatant from CHO/C28-
GUSh was incubated with OVCAR-3 cells for 1 h at 48Ct o
demonstrate cell-associated enzymatic activity. Speciﬁcity was
determined by preincubation with the anti-Ep-CAM antibody
323/A3 (10 mgm l
71) to prevent binding of the fusion protein.
Unbound material was separated from the cells by centrifugation.
The cell pellet was washed with PBS containing 0.1% BSA and
was suspended in 150 ml1m M 4-MuGlu in buffer (pH 4.2) for
measurement of b-glucuronidase activity as described above. The
reaction was stopped after 30 min and ﬂuorescence was measured.
Quality control of the fusion protein
In order to determine the binding and enzyme activity of the
fusion protein as compared to the antibody and the enzyme alone,
we transiently transfected COS-7 cells with pSTCF/C28, pcDNA3.1-
mycHis/GUSh or pC28GUSh. Cell lysates of transfected cells were
analyzed on Western blot by anti-myc staining as described above.
The intensity of all three protein bands was quantiﬁed using an
imaging densitometer (Model GS-690, Biorad). Based on this
semi-quantitative method, equal amounts of C28 and C28GUSh
protein were used for FACS analysis on OVCAR-3 cells as
described above. An enzyme activity assay was performed, as
described above, with comparable amounts of GUSh and
C28GUSh.
In vitro antiproliferative effects
The in vitro antiproliferative effects of the prodrug DOX-GA3 on
OVCAR-3 cells incubated with C28-GUSh fusion protein were
determined as previously described (Haisma et al, 1998b). In a
separate sample, preincubation with an excess of anti-Ep-CAM
antibody 323/A3 (10 mgm l
71) was done to evaluate binding speci-
ﬁcity of C28-GUSh. After 96 h the wells were incubated with cell
proliferation reagent WST-1 (Roche) for 1 h at 378C. The absor-
bance was measured at a wavelength of 450 nm. The
antiproliferative effects were determined and expressed as IC50
values, the concentrations that give 50% growth inhibition
compared with control cell growth.
Bystander effect
CHO/C28-GUSh cells were plated together with Ep-CAM positive
OVCAR-3 cells, or as a negative control with the Ep-CAM nega-
tive cell line U118, at a ratio of 1:10 in a six-well plate
(2610
5 cells per well), and were grown for 72 h. Then, cells were
washed three times with culture medium to remove unbound
fusion protein and were incubated with 10 mM DOX-GA3 for
8 h. Cells were ﬁxed with 3.7% paraformaldehyde and permeabi-
lized with 0.2% Triton. Expression of C28-GUSh was detected by
indirect immunoﬂuorescence with mouse anti-myc antibody 9E10
(Chan et al, 1987) and ﬂuorescein-conjugated rabbit anti-mouse
secondary antibody (Dako) using confocal laser scan microscopy.
Converted prodrug was seen as red autoﬂuorescence of the nuclei,
due to DNA-intercalating doxorubicin, with an emission maxi-
mum of 600 nm.
RESULTS
Construction of C28-GUSh fusion protein
The plasmid pC28-GUSh was constructed as shown in Figure 1.
The cDNA encoding the anti-Ep-CAM scFv C28 was isolated from
a pHEN vector and inserted into the pSTCF vector (Arafat et al,
2000). The cDNA encoding GUSh was inserted in frame with the
scFv separated by a 15-amino-acid linker segment containing
(Gly4Ser)2 ﬂanked on both sides by three alanine residues, encoded
by the NotI sites. The signal peptide of GUSh was removed. The
open reading frame encoded a recombinant protein, which after
cleavage of the secretory signal sequence was composed of 913
amino acids with a predicted molecular mass of 102 kDa, including
a myc- and 6His-tag at the C-terminus.
Expression and characterisation of the fusion protein
A stable CHO cell line expressing C28-GUSh fusion protein was
constructed. Clones were screened for b-glucuronidase activity in
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Figure 1 Schematic representation of the C28-GUSh expression cassette. The structural elements include the cytomegalovirus (CMV) promotor, IgG
kappa leader sequence (L), and a C-terminal myc- and 6His-tag (mycHis) for easy detection and puriﬁcation. The anti-Ep-CAM scFv C28 is inserted as
an SﬁI/NotI fragment. The gene encoding GUSh is inserted as a NotI/NotI fragment, but not before the (Gly4Ser)2 linker is inserted in the NotI and ApaI
restriction sites. The primers encoding the linker were designed in such a way that the NotI site at the 3' end of the scFv disappeared upon downstream
insertion, and a new one is introduced at the 3' end of the linker.
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further evaluation and was called CHO/C28-GUSh. Secreted fusion
protein present in the supernatant of these cells was analysed by
SDS–PAGE and Western blotting with an anti-myc antibody.
The fusion protein monomers migrated with an apparent molecu-
lar weight of about 100 kDa (Figure 2). The apparent molecular
mass under non-denaturing conditions as determined by size
exclusion chromatography was approximately 403 kDa (data not
shown), which is in agreement with GUSh being active as a tetra-
mer (Brot et al, 1978).
The binding of the fusion protein in CHO/C28-GUSh super-
natant to Ep-CAM expressing OVCAR-3 cells was demonstrated
by FACS analysis (Figure 3A). Supernatant from untransfected
CHO cells served as negative control. Binding of functional fusion
protein was conﬁrmed by an assay for cell-associated enzyme activ-
ity (Figure 3B). There was indeed b-glucuronidase activity
associated with cells incubated with CHO/C28-GUSh supernatant,
and not with cells incubated with supernatant from untransfected
CHO cells. This activity was speciﬁcally bound to Ep-CAM,
because incubation with an excess of the anti-Ep-CAM antibody
323/A3 together with CHO/C28-GUSh supernatant resulted in a
signiﬁcantly reduced level of b-glucuronidase activity bound to
OVCAR-3 cells.
In order to determine the binding and enzyme activity of the
fusion protein as compared to the antibody and the enzyme alone,
we performed, respectively, a FACS analysis and an enzyme activity
assay with comparable amounts of protein. The binding of
C28GUSh to OVCAR-3 cells was at least 50% of that from a
comparable amount of C28 alone. Furthermore, the enzyme activ-
ity of C28GUSh was also at least 50% of the activity of GUSh alone
(data not shown).
Prodrug activation and antiproliferative effects
OVCAR-3 cells were used to determine the speciﬁc activation of
the prodrug DOX-GA3 by C28-GUSh to doxorubicin.
Under the experimental conditions used, the IC50 value for
doxorubicin in OVCAR-3 cells was 5 mM, which conﬁrmed the
2.5 mM value calculated in a previous experiment (Houba et al,
2001a). This relatively high IC50 value could probably be explained
by the use of U-bottom wells, in which the cells do not grow as a
monolayer, but more like a spheroid. Therefore, not all cells are in
direct contact with the drug. This might cause the relatively high
IC50 value of doxorubicin in our system.
The prodrug alone was relatively non-toxic with an IC50 value of
approximately 60 mM. To determine the effects of prodrug comple-
tely hydrolysed by the enzyme, an excess of b-glucuronidase
(0.25 U ml
71) was used. Indeed, the IC50 value was the same as
the IC50 value for doxorubicin, namely about 5 mM. In other
words, the prodrug was completely converted to doxorubicin.
Similarly, preincubation of OVCAR-3 cells with C28-GUSh
increased the antiproliferative effects of the prodrug as the IC50
value decreased from 60 to 10 mM as a result from activation
(Figure 4). This effect could be inhibited almost completely by
preincubation with the anti-Ep-CAM antibody 323/A3.
In order to assess a potential bystander effect due to prodrug
conversion by secreted and targeted GUSh, we mixed CHO/C28-
GUSh with OVCAR-3 or U118 cells, representing, respectively,
Ep-CAM positive and Ep-CAM negative cells. For this purpose,
we made use of the strong autoﬂuorescence of doxorubicin.
DOX-GA3 is hydrophilic and cannot pass cell membranes. After
cleavage of the prodrug, the generated hydrophobic doxorubicin
can pass cell membranes and can be detected as red nuclear ﬂuor-
escence within the cells. This experiment was carried out with 10%
C28-GUSh expressing cells and 90% OVCAR-3 or U118 cells.
Three days after plating, cells were washed to discard unbound
fusion protein and prodrug was added for 8 h. The presence of
C28-GUSh was visualised by indirect immunohistochemistry for
myc-tagged protein.
OVCAR-3 cells showed membrane staining by bound C28-GUSh
(Figure 5A, green ﬂuorescence), whereas the membranes of the
Ep-CAM negative U118 cells mixed with CHO/C28-GUSh cells
did not contain staining (Figure 5B). All nuclei of OVCAR-3 cells
mixed with CHO/C28-GUSh cells were strongly positive for doxo-
rubicin (Figure 5A, red ﬂuorescence). This is the result of prodrug
conversion by membrane-bound fusion protein, as no nuclei
stained positive for doxorubicin in the wells containing U118 cells
mixed with CHO/C28-GUSh cells (Figure 5B). Furthermore,
untransfected CHO cells mixed with OVCAR-3 cells did also not
show any membrane staining and prodrug conversion (data not
shown). The cytosol of C28-GUSh expressing CHO cells stained
strongly positive for myc-tagged fusion protein. Due to the high
levels of C28-GUSh in CHO cells, cytosolic ﬂuorescence detected
with the anti-myc antibody interfered with doxorubicin autoﬂuor-
escence resulting in yellow staining instead of green.
DISCUSSION
We have constructed an expression plasmid for the production of a
single-chain antibody-enzyme fusion protein composed of the
human anti-Ep-CAM scFv antibody C28 and the human lysosomal
enzyme GUS. The C28-GUSh fusion protein was expressed by
eukaryotic CHO cells containing the expression construct and
secreted into the supernatant of these cells. The fusion protein
was present as a tetramer in the supernatant. The secreted fusion
protein retained at least 50% of enzymatic activity, bound speciﬁ-
cally to Ep-CAM-expressing cells, and was able to convert the
glucuronide-prodrug DOX-GA3. We expect that the activation rate
for the conversion of prodrug to drug is comparable to the activa-
tion rate by the enzyme alone, as we have previously shown for a
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Figure 2 Western blot analysis of the C28-GUSh fusion protein. The
molecular weight of C28-GUSh was determined by SDS–PAGE/Western
blot using an anti-myc antibody 9E10 (Chan et al, 1987). The sizes of the
molecular mass markers (Kaleidoscope prestained standards, Biorad) are
indicated on the left. Lane 1: supernatant of the stable CHO/C28GUSh cell
line. Lane 2: supernatant of untransfected CHO cells. The apparent mass of
the full length C28-GUSh fusion protein is approximately 100 kDa, as
expected.
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glucuronidase (Haisma et al, 1998b). The C28-GUSh fusion protein
is fully functional and could therefore be useful for selective activa-
tion of a relatively non-toxic prodrug at the site of the tumour.
A fully human fusion protein is less likely to elicit an immune
response in patients than a fusion protein containing non-human
peptides. The immune response in patients has been reported to
limit ADEPT to only one cycle of treatment (Sharma et al,
1992). In that particular study, human anti-mouse antibodies
(HAMA) and human anti-enzyme antibodies were detected in all
patients treated with a mouse monoclonal antibody conjugated
to the bacterial enzyme carboxypeptidase G2. The immunosuppres-
sive agents, cyclosporin A or deoxyspergualin, can delay the host
immune response allowing two or three cycles of treatment to be
given (Dhingra et al, 1995; Bagshawe and Sharma, 1996). Cyclos-
porin A, however, leads to additional toxicity. Development of
HAMA and human anti-enzyme antibodies might be prevented
by using a human antibody and a human enzyme.
Previously, the functional characterisation of a fusion protein
consisting of the humanized fragment of an anti-CEA monoclonal
antibody and GUSh expressed in BHK cells has been reported
(Bosslet et al, 1992). The use of a humanised antibody fragment
in a fusion protein is not ideal. Although humanised antibodies
are less immunogenic than murine antibodies, anti-idiotypic anti-
bodies can develop as was shown in patients as well as in Rhesus
monkeys (Reimann et al, 1997; Richards et al, 1999). This may
be due to the variable regions of humanised antibodies being still
of murine origin.
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Figure 3 (A) Binding of the secreted C28-GUSh fusion protein to OVCAR-3 cells as measured by FACS. Ep-CAM positive OVCAR-3 cells were incu-
bated with supernatant of the CHO/C28-GUSh cell line (solid line). OVCAR-3 cells exposed to supernatant of untransfected CHO cells served as a negative
control (dotted line). Binding was visualised with mouse anti-myc antibody and ﬂuorescein-conjugated rabbit anti-mouse IgG. (B) OVCAR-3 cells incubated
with supernatant derived from CHO/C28-GUSh (lane 2) or untransfected CHO cells (lane 1) were analysed for cell-associated enzyme activity. Binding
speciﬁcity was tested by incubating OVCAR-3 cells with supernatant of CHO/C28-GUSh together with an excess of the anti-Ep-CAM antibody, 323/
A3 (lane 3). Unbound material was separated from the cells by centrifugation. The pelleted cells were incubated with 1 mM 4-MuGlu as a substrate
and ﬂuorescence was measured after 30 min.
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(5), 811–818As an alternative to ADEPT, gene-directed enzyme prodrug
therapy (GDEPT) is currently under study. In the GDEPT
approach, the gene encoding the enzyme is delivered selectively
to tumour cells. The advantage of GDEPT is that the enzyme is
continuously produced by the transduced cells, resulting in accu-
mulation of the enzyme in the tumour. It has recently been
shown that GDEPT using tumour cells expressing a secreted form
of GUSh is effective in induction of tumour cell killing in vitro and
in vivo (Weyel et al, 2000). The presence of approximately 7%
transduced cells was sufﬁcient to obtain a therapeutic effect in a
mouse model. A potential disadvantage is, however, that un-
targeted GUSh may leak from the tumour, resulting in conversion
of prodrug outside of the tumour area. In fact, leakage of GUS
from the site of production has been demonstrated (Stein et al,
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Figure 4 Antiproliferative effects of doxorubicin, DOX-GA3, and activated DOX-GA3. Cells were incubated with supernatant of CHO/C28-GUSh with-
out or with preincubation with an anti-Ep-CAM antibody as blocking agent or PBS. Cells were then seeded in 96-well plates and exposed to drug or prodrug
in triplo. As a control, cells were grown in the presence of 0.25 U ml
71 GUSh and prodrug. After 72 h, cell growth was measured with a protein dye, WST-
1, and the IC50 values were determined.
AB
Figure 5 Tumour-speciﬁc prodrug conversion by C28GUSh. CHO/C28-GUSh cells were plated after mixture with Ep-CAM positive OVCAR-3 cells (A)
or Ep-CAM negative U118 cells (B), as a negative control, at a ratio of 1:10. After 3 days of growth, medium was aspirated and cells were washed and
subsequently incubated with medium containing 10 mM DOX-GA3 for 8 h. Thereafter, cells were ﬁxed and C28-GUSh expressing cells and cells which had
bound C28-GUSh were detected by indirect immunoﬂuorescence using an anti-myc antibody and a ﬂuorescein conjugated secondary antibody (green stain-
ing). Prodrug conversion is visualised as the red nuclear staining of doxorubicin within the cells.
A fully human scFv-beta-glucuronidase fusion protein
M de Graaf et al
816
British Journal of Cancer (2002) 86(5), 811–818 ã 2002 Cancer Research UK1999). The aim of that study was correction of mucopolysacchar-
idosis type VII, a lysosomal storage disease caused by a
deﬁciency in functional GUS. For systemic correction of GUS deﬁ-
ciency, diffusion of the enzyme from the liver is necessary. Indeed,
after intravenous delivery of an adenovirus expressing GUS result-
ing in transduction of mainly liver cells, the investigators found
corrective levels of GUS activity in blood and uptake at sites that
are poorly transduced, such as kidneys and lungs.
In GDEPT, diffusion of the enzyme from the tumour should be
prevented at all costs, as it will negatively affect tumour selectivity.
The solution to this problem could be secretion of a targeted form
or a surface tethered form of GUSh by transduced tumour cells, as
it might result in retention of the enzyme within the tumour.
Recently, a surface tethered form of GUSh has been constructed
by fusion of the transmembrane domain of the human PDGF
receptor to a C-terminally truncated form of GUSh (Heine et al,
2001). This GDEPT system has been shown to produce a potent
anti-tumour effect in vivo. We hypothesise that secretion of a
targeted form of GUSh may result in a more pronounced bystander
effect, as the enzyme will diffuse within the tumour and bind to
neighbouring antigen-positive cells. The C28-GUSh construct is a
possible candidate for this purpose. In view of this, we have shown
in vitro that 10% of C28-GUSh expressing cells sufﬁce to achieve
uptake of doxorubicin into all cells in the population. Moreover,
the secreted fusion protein C28-GUSh could bind speciﬁcally to
untransduced, Ep-CAM positive cells. This is very important for
future in vivo application, as not all cells in the tumour will be
transduced with the fusion construct.
In summary, we have engineered a fully human and functional
fusion protein for future application in selective chemotherapy.
This construct could be produced on a large-scale for ADEPT. In
addition, it could be used for cancer gene therapy. In the latter
case, the fusion protein would be produced locally within the
tumour by infected tumour cells, and bind to the relevant antigen.
The secretion of a targeted enzyme within the tumour should
ensure a high therapeutic index for a clinically important cytotoxic
drug when activated speciﬁcally at the site of the tumour.
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